Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation

BioCentury This Week

BioCentury's editors break down CMS’s final coverage decision on amyloid mAbs for Alzheimer’s disease, focusing on what the lessons are from Aduhelm’s journey through FDA and CMS, and what sponsors of the next crop of Alzheimer's therapies should expect when seeking approval of their programs. Plus: highlights from the latest translational coverage in BioCentury’s Distillery, a call from FDA’s Patrizia Cavazzoni for increased funding to support regulatory innovation, and takeaways from Editor in Chief Simone Fishburn’s conversation on The BioCentury Show with EQRx Inc.’s Jami Rubin.

Reach us by sending a text

2022-04-11 23 min 4 chapters

Available Results

Generated results are saved to the knowledge database for reuse and search.

No generated results are available for this episode yet.

Extract Knowledge

Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.

Generated results for public episodes are saved to the knowledge database so they can be reused and searched later.
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in